| Title: |
Serum microRNA-146a-5p and microRNA-221-3p as potential clinical biomarkers for papillary thyroid carcinoma |
| Authors: |
Verrienti A.; Pecce V.; Grani G.; Del Gatto V.; Barp S.; Maranghi M.; Giacomelli L.; Di Gioia C.; Biffoni M.; Filetti S.; Durante C.; Sponziello M. |
| Contributors: |
Verrienti, A.; Pecce, V.; Grani, G.; Del Gatto, V.; Barp, S.; Maranghi, M.; Giacomelli, L.; Di Gioia, C.; Biffoni, M.; Filetti, S.; Durante, C.; Sponziello, M. |
| Publisher Information: |
SPRINGER; ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES |
| Publication Year: |
2024 |
| Collection: |
Sapienza Università di Roma: CINECA IRIS |
| Subject Terms: |
Biomarker; Circulating miRNA; Liquid biopsy; Papillary thyroid cancer; Patient follow-up |
| Description: |
PurposePapillary thyroid carcinoma (PTC) is the most common malignant thyroid neoplasm, accounting for approximately 85% of all follicular cell-derived thyroid nodules. This study aimed to assess the diagnostic potential of circulating microRNA-146a-5p and microRNA-221-3p as biomarkers for PTC and their usefulness in monitoring disease progression during patient follow-up.MethodsAn observational study was conducted on two cohorts of PTC patients and healthy controls (HCs) using digital PCR. We collected patients' clinical, biochemical, and imaging data during the post-surgery surveillance. We analyzed the levels of circulating miRNAs in serum samples of patients before surgery and during the follow-up, including those with indeterminate/biochemical incomplete response (IndR/BIR) and residual thyroid tissues (Thy Residue).ResultsBoth miR-146a-5p and miR-221-3p were confirmed as effective biomarkers for PTC diagnosis. They enabled differentiation between pre-surgery PTC patients and HCs with an area under the curve (AUC) of 92% and 87.3%, respectively, using a threshold level of 768,545 copies/uL for miR-146a-5p and 389,331 copies/uL for miR-221-3p. It was found that miRNA fold change levels, rather than absolute levels, can be useful during patient follow-up. In particular, we found that a fold change of 2 for miR-146a-5p and 2.2 for miR-221-3p can identify a progressive disease, regardless of the presence of TgAbs or remnant thyroid.ConclusionMiRNA-146a-5p and miRNA-221-3p, particularly the former, could be valuable diagnostic biomarkers for PTCs. They also seem to be effective in monitoring disease progression during patient follow-up by evaluating their fold change, even when thyroglobulin is uninformative. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/39298113; info:eu-repo/semantics/altIdentifier/wos/WOS:001315852500001; journal:JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION; https://hdl.handle.net/11573/1720856 |
| DOI: |
10.1007/s40618-024-02467-3 |
| Availability: |
https://hdl.handle.net/11573/1720856; https://doi.org/10.1007/s40618-024-02467-3 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.3F4EA030 |
| Database: |
BASE |